Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Edgewise Therapeutics Inc
(NQ:
EWTX
)
18.75
+0.33 (+1.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Edgewise Therapeutics Inc
< Previous
1
2
3
Next >
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16
February 02, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
January 05, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study
December 15, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2
November 17, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Third Quarter 2021 Financial Results
November 10, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients
October 28, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 23
September 14, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)
August 16, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Second Quarter 2021 Financial Results
August 09, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11
August 04, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skeletal Muscle Conference
June 22, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 01, 2021
From
Edgewise Therapeutics, Inc.
Via
Business Wire
Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights
May 13, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy
May 04, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer
April 27, 2021
From
Edgewise Therapeutics
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.